Sexual Dysfunction in Women
Sexual Dysfunction in Women
Many women will likely experience a sexual problem in their lifetimes. Female sexual dysfunction (FSD) is a broad term used to describe three categories of disorders of a multifactorial nature. Efficacious but limited pharmacotherapeutic options exist to address FSD. The FDA recently approved the first agent for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use of hormonal therapies, particularly estrogen and testosterone, are the most widely employed for FSD, particularly in postmenopausal women. Other drugs currently under investigation include phosphodiesterase inhibitors and agents that modulate dopamine or melanocortin receptors. Pharmacists should be aware of the classifications of FSD and the options that are currently available for treatment.
Many women will likely experience a sexual problem in their lifetimes. The Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking (PRESIDE) study surveyed more than 30,000 U.S. women aged ≥18 years regarding sexual function. Results from this study estimated that 12% of women experience a diagnosable sexual disorder that causes personal distress, with lack of sexual desire being the most prevalent.
Female sexual dysfunction (FSD) is a complex interplay of biological, hormonal, and psychological factors that can have a significant negative effect on female sexual health and quality of life. FSD can be influenced by several dynamics, including advancing age, social factors, psychosocial stress, and trauma.
Abstract and Introduction
Abstract
Many women will likely experience a sexual problem in their lifetimes. Female sexual dysfunction (FSD) is a broad term used to describe three categories of disorders of a multifactorial nature. Efficacious but limited pharmacotherapeutic options exist to address FSD. The FDA recently approved the first agent for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Off-label use of hormonal therapies, particularly estrogen and testosterone, are the most widely employed for FSD, particularly in postmenopausal women. Other drugs currently under investigation include phosphodiesterase inhibitors and agents that modulate dopamine or melanocortin receptors. Pharmacists should be aware of the classifications of FSD and the options that are currently available for treatment.
Introduction
Many women will likely experience a sexual problem in their lifetimes. The Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking (PRESIDE) study surveyed more than 30,000 U.S. women aged ≥18 years regarding sexual function. Results from this study estimated that 12% of women experience a diagnosable sexual disorder that causes personal distress, with lack of sexual desire being the most prevalent.
Female sexual dysfunction (FSD) is a complex interplay of biological, hormonal, and psychological factors that can have a significant negative effect on female sexual health and quality of life. FSD can be influenced by several dynamics, including advancing age, social factors, psychosocial stress, and trauma.
